Do β-blockers prolong survival in heart failure only by inhibiting the β 1 -receptor? A perspective on the results of the COMET trial
β受体阻滞剂是否仅通过抑制β1受体来延长心力衰竭患者的生存期?对彗星试验结果的展望
作者: Milton Packer
作者单位: 1From the Division of Circulatory Physiology, Columbia University College of Physicians and Surgeons, New York, New York USA
刊名: Journal of Cardiac Failure, 2003, Vol.9 (6), pp.429-443
来源数据库: Elsevier Journal
DOI: 10.1016/j.cardfail.2003.08.003
关键词: CarvedilolMetoprololΒ 1 -adrenergic blockadeDose-response relations
原始语种摘要: Abstract(#br)Experimental and clinical studies indicate that carvedilol exerts multiple antiadrenergic effects in addition to β 1 -receptor blockade, but the prognostic importance of these actions has long been debated. This controversy has now been substantially advanced by the results of the recently completed Carvedilol Or Metoprolol European Trial (COMET), which showed that carvedilol (25 mg twice daily) reduced mortality by 17% when compared with metoprolol (50 mg twice daily), P
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:3.32 (2012)

×
关键词翻译
关键词翻译
  • COMET COmputer MEssage Transmission
  • trial 试验
  • metoprolol 美托洛尔
  • prolong 拉长
  • inhibiting 抑制
  • receptor 接受体
  • antiadrenergic 抗肾上腺素能的
  • failure 破坏
  • heart 心脏
  • survival 生存